The debate about the funding of Herceptin: A case study of 'countervailing powers'

Social Science and Medicine

Volumn 75, Issue 12, 2012, Pages 2353-2361

  Gabe, Jonathan ^a   Chamberlain, Kerry ^b   Norris, Pauline ^c   Dew, Kevin ^d   Madden, Helen ^b   Hodgetts, Darrin ^e  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b MASSEY UNIVERSITY   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^e UNIVERSITY OF WAIKATO   (New Zealand)

Author keywords

Countervailing powers; Health consumer groups; Herceptin; Media; Medication controversies; New Zealand; Pharmaceutical companies; Regulators

Indexed keywords

TRASTUZUMAB;

CANCER; DECISION MAKING; DISEASE TREATMENT; GOVERNANCE APPROACH; MEDIA ROLE; MEDICINE; PHARMACEUTICAL INDUSTRY; REGULATORY FRAMEWORK; WOMENS HEALTH;

ARTICLE; BREAST CANCER; CONSUMER; COUNTERVAILING POWER; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; FUNDING; GOVERNMENT; GOVERNMENT REGULATION; HEALTH ECONOMICS; HUMAN; MASS MEDIUM; PATIENT CARE; SOCIAL CONTROL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CONFLICT (PSYCHOLOGY); DRUG INDUSTRY; FEMALE; FINANCING, GOVERNMENT; GOVERNMENT REGULATION; HUMANS; MASS MEDIA; NEW ZEALAND; PATIENT ADVOCACY;

NEW ZEALAND;

EID: 84869503910     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2012.09.009     Document Type: Article

References (69)

1. Abraham J. Partial progress: governing the pharmaceutical industry and the NHS, 1948-2008. Journal of Health Politics, Policy and Law 2009, 34(6):931-977.
2. Abraham J. The pharmaceutical industry, the state and the NHS. The new sociology of the health service 2009, Routledge, London. J. Gabe, M. Calnan (Eds.).
3. Barrett A., Roques T., Small M., Smith R.D. How much will Herceptin really cost?. British Medical Journal 2006, 333:1118-1120.
4. Bazell R. The making of Herceptin, a revolutionary treatment for breast cancer 1998, Random House, New York.
5. BCAC press release Herceptin petition sends strong message 23 August 2007, Available from. http://www.breastcancer.org.nz/Herceptinpetition.htm.
6. Benelli E. The role of media in steering public opinion on healthcare issues. Health Policy 2003, 63(2):179-186.
7. Braae R., McNee W., Moore D. Managing pharmaceutical expenditure while increasing access. The Pharmaceutical Management Agency (PHARMAC) experience. Pharmacoeconomics 1999, 16(6):649-960.
8. Brougham M. Nine-week promise. Herald on Sunday 2008, August 10, 30.
9. Burgess E.P.J. Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article. The New Zealand Medical Journal 2006, 119(1237). Retrieved on 30.03.10 from. http://www.nzma.org.nz/journal/119-1237/2065/.
10. Burgess E. Submission to Health Select Committee on the Anne Hayden Herceptin petition by the Breast Cancer Aotearoa Coalition (BCAC) 2006, Available from. http://www.breastcancer.org.nz/press_herceptin1.htm.
11. Busfield J. Globalization and the pharmaceutical industry revisited. International Journal of Health Services 2003, 33:581-605.
12. Busfield J. Pills, power, people: sociological understandings of the pharmaceutical industry. Sociology 2006, 40:297-314.
13. Busfield J. 'A pill for every ill': explaining the expansion in medicine use. Social Science & Medicine 2010, 70:934-941.
14. Cassels A., Hughes M., Cole C., Mintzes B., Lexchin J., McCormack J. Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. Canadian Medical Association Journal 2003, 168:1133-1137.
15. Cheng D. Breast cancer drug excites doctors; risk of an aggressive cancer recurring reduced by 46%. The New Zealand Herald 3 June 2005.
16. Daemmrich A. Pharmacopolitics 2004, University of North Carolina Press, Chapel Hill.
17. Dent R., Clemons M. Adjuvant trastuzumab for breast cancer. British Medical Journal 2005, 331:1035-1036.
18. Economist Back to the lab; Roche digests Genentech. The Economist (US) 2009, 393(8661). 65EU.
19. Elias P. Biotech giants wage war over cancer drug Herceptin focus of profit, patent debate. The Seattle Times August 7 2002.
20. " 'Funeral march' protest against Herceptin ruling" The New Zealand Herald 2006, August 1, 1.
21. Gabe J., Bury M. Halcion nights: a sociological account of a medical controversy. Sociology 1996, 30:447-469.
22. Genentech reports solid results for 2008 boosted by Avastin, but analysts negative. (2009, 26 January). Pharma Marketletter.
23. Giddens A. The consequences of modernity 1990, Polity Press, Cambridge.
24. Grilli R., Ramsay C., Minozzi S. Mass media interventions: effects on health services utilisation. Cochrane Database of Systematic Reviews 2002, 1:CD000389. 10.1002/14651858.CD000389.
25. Hartley H. The system of alignments challenging physician professional dominance: an elaborated theory of countervailing powers. Sociology of Health & Illness 2002, 24(2):178-207.
26. Hartley H., Coleman C.L. News media coverage of direct-to-consumer pharmaceutical advertising: implications for countervailing powers theory. Health 2007, 12(1):107-132.
27. Hayden A. Submission on petition to the Health Committee of the House of Representatives 2006, Available from. http://www.breastcancer.org.nz/press_herceptin11.htm.
28. Hayman K. High-cost cancer drug rejected. The Press 2006, July 29, 3.
29. Hedgecoe A. 'At the point at which you can do something about it, then it becomes more relevant': informed consent in the pharmacogenetic clinic. Social Science & Medicine 2005, 61:1201-1210.
30. Hedgecoe A. It's money that matters: the financial context of ethical decision-making in modern biomedicine. Sociology of Health & Illness 2006, 28:768-784.
31. Hodgetts D., Chamberlain K., Scammell M., Nikora L., Karapu R. Constructing health news: media production and the possibilities for a civic-oriented journalism. Health 2007, 12:43-66.
32. Hortobagyi G. Trastuzumab in the treatment of breast cancer. New England Journal of Medicine 2005, 353(16):1734-1736.
33. Isaacs R.J., Frampton C.M., Kuper-Hummel M.J. PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision. New Zealand Medical Journal 2007, 120(1259).
34. Johnson-Cartee K.S. News narrative and news framing: Constructing political reality 2005, Rowman and Littlefield, Lanham, MD.
35. Key J. Government honours Herceptin promise 2008, December 10, Press Release, New Zealand Government, Available. http://www.beehive.govt.nz/release/government-honours-herceptin-promise.
36. Lancet Editorial Herceptin and early breast cancer: a moment for caution. The Lancet 2005, 366(9498):1673.
37. Law J. Resisting big pharma. Soundings: A Journal of Politics and Culture 2007, 127-136. 35.
38. Light D.W. Professionalism as a countervailing power. Journal of Health Politics, Policy and Law 1991, 16:499-506.
39. Light D.W. Countervailing powers: a framework for professions in transition. Health professions and the state in Europe 1995, Routledge, London. T. Johnson, G. Larkin, M. Saks (Eds.).
40. Light D.W. The rhetorics and realities of community care: the limits of countervailing power to meet the health care needs of the twenty-first century. Journal of Health Politics, Policy and Law 1997, 22:105-145.
41. Light D.W. Health care professions, markets, and countervailing powers. Handbook of medical sociology 2010, 270-289. Vanderbilt University Press, Nashville. 6th ed. C. Bird (Ed.).
42. Light D.W. Bearing the risks of prescription drugs. The risks of prescription drugs 2010, 1-39. Columbia University Press, New York. D.W. Light (Ed.).
43. MacKenzie R., Chapman S., Salkeld G., Holding S. Media influence on Herceptin subsidization in Australia: application of the rule of rescue?. Journal of the Royal Society of Medicine 2008, 101:305-312.
44. Metcalfe S., Evans J. PHARMAC responds on Herceptin assumptions and decisions. New Zealand Medical Journal 2007, 120(1260):1-7.
45. Metcalfe S., Burgess C., Laking G., Evans J., Wells S., Crausaz S. Trastuzumab: possible publication bias. The Lancet 2008, 371:1644-1646.
46. Metcalfe S., Evans J., Priest G. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer. The New Zealand Medical Journal 2007, 120(1256):1-20.
47. Miles D.W. Update on HER-2 as a target for cancer therapy Herceptin in the clinical setting. Breast Cancer Research 2001, 3:380-384.
48. Milner M. Roche rebuffs new overtures from Novartis. The Guardian 27 February 2003, 28.
49. Nahuis R., Boon W. The impact of patient advocacy: the case of innovative breast cancer drug reimbursement. Sociology of Health & Illness 2011, 33(1):1-15.
50. New Zealand Press Association Breast cancer coalition urges fast-track funding of drug September 8 2005, New Zealand Press Association.
51. NICE Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer 2006, Available. http://www.guidance.nice.org.uk/TA107.
52. Petersen S. Roche responds to the 'Herceptin or deception' article. New Zealand Medical Journal 2006, 119(1237).
53. PHARMAC PHARMAC annual review 2005 2005, Available. http://www.pharmac.govt.nz/2005/11/10/ARev05.pdf.
54. PHARMAC Herceptin not funded, under continuing review. Media release 2006, Available. http://www.pharmac.govt.nz/2006/07/28/280706.pdf.
55. PHARMAC Proposal regarding the funding of 12 months treatment with Herceptin trastuzumab for HER 2 positive early breast cancer 2008, Available. http://www.pharmac.govt.nz/2008/05/05/Proposal%20regarding%20the%20funding%20of%2012%20months%20treatment%20with%20trastuzumab%20for%20HER%202%20positive%20breast%20cancer.pdf.
56. PHARMAC PHARMAC reaffirms confidence in 9 week Herceptin treatment 2008, Available. http://www.pharmac.govt.nz/2008/08/07/Herceptin%20media%20release%207%20August%202008.pdf.
57. PHARMAC Approval of proposal to amend the access criteria for trastuzumab (Herceptin) in the pharmaceutical schedule 2010, Available. http://www.pharmac.govt.nz/2010/06/04/2010-06-0%20Notification_%20approval%20of%20proposal%20to%20list%2012%20months%20trastuzumab.pdf.
58. Ragupathy, R., Aaltonen, K., Tordoff, J., Norris, P. & Reith, D. A 3-dimensional view of licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand. Pharmacoeconomics, in press.
59. Relman A.S. The new medical-industrial complex. New England Journal of Medicine 1980, 303:963-970.
60. Renahy E., Chauvin P. Internet uses for health information seeking: a literature review. Revue d'épidémiologie et de Santé Publique 2006, 54:263-275.
61. Roche Press Release Research shows breast cancer reoccurrence halved. Scoop Independent News 2005.
62. Roche Press Release Collaboration on additional funding for treatment. Scoop Independent News 2005.
63. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. New England Journal of Medicine 2005, 353:1659-1672.
64. Rosevear M. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?. The New Zealand Medical Journal 2006, 119(1235).
65. Schwitzer G. How do US journalists cover treatments, tests, products, and procedures? An evaluation of 500 stories. PLoS Medicine 2008, 5(5):e95.
66. Seale C. Media and health 2002, Sage, London.
67. Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Social Science & Medicine 2008, 66:1909-1914.
68. Walsh & Ors v PHARMAC & Anor High court, Wellington 3 April 2008, CIV 2007-485-1386, Available at. http://www.pharmac.govt.nz/2008/04/02/090408.pdf.
69. Your money or your life The New Zealand Herald 2001, August 6.